Pharming Stock Based Compensation vs Capital Expenditures Analysis

PHAR Stock

USD 10.01 0.48 5.04%

Pharming Group financial indicator trend analysis is much more than just breaking down Pharming Group NV prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Pharming Group NV is a good investment. Please check the relationship between Pharming Group Stock Based Compensation and its Capital Expenditures accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Stock Based Compensation vs Capital Expenditures

Stock Based Compensation vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Pharming Group NV Stock Based Compensation account and Capital Expenditures. At this time, the significance of the direction appears to have almost no relationship.

The correlation between Pharming Group's Stock Based Compensation and Capital Expenditures is 0.1. Overlapping area represents the amount of variation of Stock Based Compensation that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Pharming Group NV, assuming nothing else is changed. The correlation between historical values of Pharming Group's Stock Based Compensation and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Stock Based Compensation of Pharming Group NV are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of Stock Based Compensation i.e., Pharming Group's Stock Based Compensation and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

0.1

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Capital Expenditures

Capital Expenditures are funds used by Pharming Group NV to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Pharming Group operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Pharming Group's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Pharming Group NV current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pharming Group NV. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

At this time, Pharming Group's Selling General Administrative is relatively stable compared to the past year. As of 01/18/2025, Issuance Of Capital Stock is likely to grow to about 4 M, while Tax Provision is likely to drop (1.8 M).

	2022	2023	2024	2025 (projected)
Total Operating Expenses	169.8M	225.5M	259.3M	272.3M
Cost Of Revenue	17.6M	25.2M	29.0M	15.2M

Total Operating Expenses Cost Of Revenue

Pharming Group fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock
Total Assets		0.98	0.94	0.65	0.98	0.92	0.1	0.55	0.37	0.84	0.65	0.96	-0.16	0.99	0.91	0.91	0.7	0.96	0.89	0.71	0.87	0.98	0.99	0.04	0.79	-0.38
Short Long Term Debt Total	0.98		0.94	0.61	0.94	0.9	0.02	0.55	0.33	0.83	0.68	0.95	-0.19	0.97	0.86	0.91	0.66	0.99	0.87	0.66	0.85	0.98	0.97	0.01	0.81	-0.39
Other Current Liab	0.94	0.94		0.69	0.87	0.79	0.11	0.55	0.17	0.89	0.6	0.91	-0.19	0.92	0.86	0.81	0.66	0.93	0.83	0.66	0.83	0.97	0.93	0.09	0.77	-0.42
Total Current Liabilities	0.65	0.61	0.69		0.55	0.41	0.45	0.28	-0.14	0.6	0.47	0.8	0.07	0.54	0.66	0.38	0.28	0.52	0.46	0.29	0.82	0.72	0.56	0.71	0.87	-0.44
Total Stockholder Equity	0.98	0.94	0.87	0.55		0.95	0.11	0.51	0.52	0.77	0.64	0.91	-0.13	0.98	0.88	0.93	0.71	0.91	0.88	0.75	0.82	0.91	0.98	-0.08	0.71	-0.3
Property Plant And Equipment Net	0.92	0.9	0.79	0.41	0.95		-0.07	0.52	0.48	0.66	0.59	0.83	-0.2	0.94	0.81	0.92	0.7	0.9	0.87	0.7	0.74	0.85	0.94	-0.2	0.61	-0.27
Current Deferred Revenue	0.1	0.02	0.11	0.45	0.11	-0.07		-0.32	-0.18	0.08	0.31	0.24	0.04	0.05	0.05	0.06	-0.24	-0.06	-0.21	-0.1	0.31	0.1	0.03	0.39	0.36	-0.1
Net Debt	0.55	0.55	0.55	0.28	0.51	0.52	-0.32		0.28	0.74	-0.24	0.45	0.09	0.51	0.8	0.31	0.93	0.55	0.79	0.81	0.3	0.56	0.59	-0.01	0.23	-0.17
Retained Earnings	0.37	0.33	0.17	-0.14	0.52	0.48	-0.18	0.28		0.18	0.13	0.22	0.35	0.43	0.35	0.48	0.46	0.29	0.44	0.58	0.12	0.2	0.43	-0.44	0.06	0.37
Accounts Payable	0.84	0.83	0.89	0.6	0.77	0.66	0.08	0.74	0.18		0.31	0.78	0.0	0.81	0.88	0.64	0.8	0.82	0.82	0.8	0.66	0.87	0.84	0.06	0.63	-0.3
Cash	0.65	0.68	0.6	0.47	0.64	0.59	0.31	-0.24	0.13	0.31		0.7	-0.3	0.68	0.3	0.78	-0.05	0.66	0.32	0.05	0.73	0.64	0.61	0.01	0.75	-0.31
Non Current Assets Total	0.96	0.95	0.91	0.8	0.91	0.83	0.24	0.45	0.22	0.78	0.7		-0.09	0.91	0.86	0.82	0.55	0.89	0.78	0.58	0.9	0.97	0.91	0.27	0.9	-0.4
Non Currrent Assets Other	-0.16	-0.19	-0.19	0.07	-0.13	-0.2	0.04	0.09	0.35	0.0	-0.3	-0.09		-0.21	-0.01	-0.29	0.01	-0.26	-0.13	0.22	-0.25	-0.18	-0.19	0.26	-0.03	0.74
Cash And Short Term Investments	0.99	0.97	0.92	0.54	0.98	0.94	0.05	0.51	0.43	0.81	0.68	0.91	-0.21		0.86	0.95	0.7	0.96	0.89	0.71	0.83	0.94	0.99	-0.12	0.72	-0.35
Net Receivables	0.91	0.86	0.86	0.66	0.88	0.81	0.05	0.8	0.35	0.88	0.3	0.86	-0.01	0.86		0.69	0.88	0.82	0.93	0.83	0.73	0.89	0.9	0.16	0.64	-0.35
Common Stock Shares Outstanding	0.91	0.91	0.81	0.38	0.93	0.92	0.06	0.31	0.48	0.64	0.78	0.82	-0.29	0.95	0.69		0.53	0.92	0.76	0.58	0.78	0.84	0.92	-0.29	0.67	-0.28
Short Term Investments	0.7	0.66	0.66	0.28	0.71	0.7	-0.24	0.93	0.46	0.8	-0.05	0.55	0.01	0.7	0.88	0.53		0.66	0.89	0.93	0.42	0.65	0.76	-0.18	0.26	-0.16
Non Current Liabilities Total	0.96	0.99	0.93	0.52	0.91	0.9	-0.06	0.55	0.29	0.82	0.66	0.89	-0.26	0.96	0.82	0.92	0.66		0.87	0.66	0.81	0.96	0.96	-0.12	0.74	-0.38
Inventory	0.89	0.87	0.83	0.46	0.88	0.87	-0.21	0.79	0.44	0.82	0.32	0.78	-0.13	0.89	0.93	0.76	0.89	0.87		0.8	0.67	0.86	0.93	-0.09	0.53	-0.37
Other Current Assets	0.71	0.66	0.66	0.29	0.75	0.7	-0.1	0.81	0.58	0.8	0.05	0.58	0.22	0.71	0.83	0.58	0.93	0.66	0.8		0.43	0.64	0.75	-0.22	0.32	0.09
Other Stockholder Equity	0.87	0.85	0.83	0.82	0.82	0.74	0.31	0.3	0.12	0.66	0.73	0.9	-0.25	0.83	0.73	0.78	0.42	0.81	0.67	0.43		0.87	0.82	0.22	0.91	-0.52
Total Liab	0.98	0.98	0.97	0.72	0.91	0.85	0.1	0.56	0.2	0.87	0.64	0.97	-0.18	0.94	0.89	0.84	0.65	0.96	0.86	0.64	0.87		0.95	0.15	0.84	-0.44
Total Current Assets	0.99	0.97	0.93	0.56	0.98	0.94	0.03	0.59	0.43	0.84	0.61	0.91	-0.19	0.99	0.9	0.92	0.76	0.96	0.93	0.75	0.82	0.95		-0.09	0.71	-0.36
Short Term Debt	0.04	0.01	0.09	0.71	-0.08	-0.2	0.39	-0.01	-0.44	0.06	0.01	0.27	0.26	-0.12	0.16	-0.29	-0.18	-0.12	-0.09	-0.22	0.22	0.15	-0.09		0.43	-0.25
Intangible Assets	0.79	0.81	0.77	0.87	0.71	0.61	0.36	0.23	0.06	0.63	0.75	0.9	-0.03	0.72	0.64	0.67	0.26	0.74	0.53	0.32	0.91	0.84	0.71	0.43		-0.4
Common Stock	-0.38	-0.39	-0.42	-0.44	-0.3	-0.27	-0.1	-0.17	0.37	-0.3	-0.31	-0.4	0.74	-0.35	-0.35	-0.28	-0.16	-0.38	-0.37	0.09	-0.52	-0.44	-0.36	-0.25	-0.4

Click cells to compare fundamentals

Pharming Group Account Relationship Matchups

Pharming Group fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	419.1M	396.9M	425.8M	462.9M	532.3M	558.9M
Short Long Term Debt Total	162.2M	161.6M	166.7M	171.5M	197.3M	207.1M
Other Current Liab	58.8M	32.0M	42.3M	51.8M	59.5M	62.5M
Total Current Liabilities	77.0M	46.7M	59.7M	78.0M	89.7M	46.5M
Total Stockholder Equity	183.7M	192.7M	204.6M	218.8M	251.6M	264.2M
Property Plant And Equipment Net	21.7M	33.1M	39.1M	33.5M	38.5M	40.4M
Current Deferred Revenue	34.6M	34.3M	(44.4K)	(56.2K)	(64.7K)	(61.4K)
Net Debt	(43.3M)	(30.1M)	(40.6M)	109.8M	126.3M	132.6M
Retained Earnings	(317.5M)	(269.4M)	(256.4M)	(265.3M)	(238.7M)	(250.7M)
Accounts Payable	13.5M	5.1M	6.1M	14.5M	16.7M	17.5M
Cash	205.5M	191.7M	207.3M	61.7M	71.0M	71.7M
Non Current Assets Total	155.5M	147.7M	148.3M	146.5M	168.5M	176.9M
Non Currrent Assets Other	510.4K	(303.4K)	1.3M	1.6M	1.5M	863.7K
Cash And Short Term Investments	205.5M	191.7M	207.3M	213.4M	245.4M	257.7M
Net Receivables	19.2M	15.9M	19.6M	42.6M	49.0M	51.5M
Common Stock Shares Outstanding	853.4M	876.4M	883.9M	657.0M	755.6M	793.4M
Liabilities And Stockholders Equity	419.1M	396.9M	425.8M	462.9M	532.3M	558.9M
Non Current Liabilities Total	158.4M	157.5M	161.5M	166.1M	191.0M	200.6M
Inventory	21.2M	27.3M	42.3M	56.8M	65.3M	68.5M
Other Current Assets	5.0M	2.6M	2.5M	13.8M	12.4M	13.0M
Other Stockholder Equity	500.9M	462.7M	462.3M	479.0M	550.8M	355.2M
Total Liab	235.4M	204.2M	221.2M	244.1M	280.7M	294.7M
Total Current Assets	263.6M	249.2M	277.5M	316.3M	363.8M	382.0M
Short Term Debt	4.0M	2.4M	5.2M	5.4M	6.3M	5.9M
Intangible Assets	94.2M	83.8M	75.1M	71.3M	82.0M	43.1M
Common Stock	7.9M	7.3M	7.5M	6.9M	6.3M	5.9M
Accumulated Other Comprehensive Income	5.3M	2.2M	(8.7M)	(1.9M)	(1.7M)	(1.6M)
Other Liab	32.7M	17.3M	173K	146K	131.4K	124.8K
Net Tangible Assets	38.2M	77.2M	96.2M	129.5M	148.9M	156.4M
Long Term Debt	121.9M	122.6M	131.6M	136.6M	157.1M	95.7M
Capital Lease Obligations	8.3M	18.4M	33.3M	33.1M	38.1M	40.0M
Deferred Long Term Liab	2.2M	4.3M	4.4M	266K	239.4K	227.4K
Net Invested Capital	273.0M	294.5M	338.0M	357.2M	410.8M	258.8M
Short Long Term Debt	1.7M	1.7M	1.8M	1.8M	1.6M	1.6M
Non Current Liabilities Other	32.0M	17.3M	173K	146K	131.4K	124.8K
Net Working Capital	151.8M	178.8M	217.8M	238.4M	274.1M	287.8M
Property Plant Equipment	14.5M	17.6M	29.3M	39.1M	45.0M	47.3M

Additional Tools for Pharming Stock Analysis

When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Pharming Stock Based Compensation vs Capital Expenditures Analysis

Stock Based Compensation vs Capital Expenditures

Stock Based Compensation vs Capital Expenditures Correlation Analysis

Correlation Coefficient

Stock Based Compensation

Capital Expenditures

Pharming Group fundamental ratios Correlations

Pharming Group Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Pharming Group fundamental ratios Accounts

Additional Tools for Pharming Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Assets
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Total Current Assets	+ 0.99	Cash And Short Term Investments
Short Long Term Debt Total	+ 0.98	Total Assets
Total Stockholder Equity	+ 0.98	Total Assets

Common Stock	- 0.52	Other Stockholder Equity
Common Stock	- 0.44	Total Liab
Short Term Debt	- 0.44	Retained Earnings
Common Stock	- 0.44	Total Current Liabilities
Common Stock	- 0.42	Other Current Liab
Common Stock	- 0.4	Intangible Assets